# A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS Ⅱ

> **NCT05422482** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **GC Biopharma Corp** · enrollment: 12 (estimated)

## Conditions studied

- Mucopolysaccharidosis II
- Hunter Syndrome

## Interventions

- **BIOLOGICAL:** GC1123

## Key facts

- **NCT ID:** NCT05422482
- **Lead sponsor:** GC Biopharma Corp
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-09-20
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05422482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05422482, "A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS Ⅱ". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05422482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*